 |
PHILLIP W. BERMAN
. . . . . . . . . . . .
|
|
|
|
| |
|
| 
Research Focus
. . . . . . . . . . . . . . . . . . |
| |
| |
Phillip Berman is a pioneer in the development
of recombinant vaccines for AIDS and other infectious diseases. His research interests include the development of vaccines, therapeutics, and diagnostics for the prevention and treatment of infectious diseases, as well as the development of new technology for commercial production of complex recombinent glycoproteins.
Research history: Berman spent 15 years at Genentech, where he led research on recombinant proteins, vaccine development,
and monoclonal antibodies. In 1995, he cofounded VaxGen, where he served as senior vice president for research and development.
He oversaw VaxGen's efforts to develop an HIV vaccine and also began an anthrax vaccine program. In 2004, Berman cofounded
Global Solutions for Infectious Diseases, a nonprofit research organization dedicated to combining knowledge and expertise
from the biotechnology industry and the public health sector to address infectious disease problems in the developing world.
|
|
| |
 |
|
|
 |
 |
© January
2005,
CBSE
Updated 7/2008
|
|
|
Center for Biomolecular Science & Engineering
Engineering 2, Suite 501, Mail Stop CBSE/ITI
UC Santa Cruz, Santa Cruz, CA 95064
phone (831) 459-1544 • fax (831) 459-1809
cbseweb@soe.ucsc.edu
Questions about the UCSC Genome Browser? Email genome@soe.ucsc.edu |
|
|
 |
SELECTED
PAPERS
. . . . . . . . . . . .
|
| |
HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine
J Infect Dis, Sep 15, 2005
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
J Infect Dis, Mar 1, 2005
Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1
JAIDS, Sept 1, 2004
Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials
AIDS, Jan 24, 2003
Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates
Vaccine, Nov 12, 2001
Immunochemistry of cytochrome c. Identification of antigenic determinants through the study of hybrid molecules
J Biol Chem, Jul 10, 1980
Antibodies to purified membrane-bound ATPase from bacillus megaterium km and their reaction with protoplasts and cytoplasmic membranes
Biochim Biophys Acta, Apr 12, 1974
|
COLLABORATORS
. . . . . . . . . . . . . |
| |
Donald P. Francis, Global Solutions for Infectious Diseases
|
| |
|
|
|
